福坦替尼治疗成人持续性及慢性免疫性血小板减少症:两项3期随机安慰剂对照试验结果
两项平行、3期、多中心、随机、双盲、安慰剂对照试验(FIT1和FIT2)纳入持续性/慢性免疫性血小板减少症(ITP)患者,按2:1随机接受福坦替尼(n=101)或安慰剂(n=49),100 mg每日两次共24周,4周无应答者增至150 mg每日两次。主要终点稳定应答率福坦替尼组18% vs 安慰剂组2%(P=.0003)。
要点
- 福坦替尼组稳定应答率18%,安慰剂组2%(P=.0003)。
- 福坦替尼组总体应答率43%,安慰剂组14%(P=.0006)。
- 最常见不良事件为腹泻(31% vs 15%)和高血压(28% vs 13%)。
核心结论
- 福坦替尼在ITP患者中产生有临床意义的应答,包括脾切除、促血小板生成药物和/或利妥昔单抗治疗失败者。
- 福坦替尼是靶向ITP发病重要机制的新型治疗选择。
研究设计与样本
- 两项平行、3期、多中心、随机、双盲、安慰剂对照试验(FIT1和FIT2)。
- 持续性/慢性ITP患者按2:1随机接受福坦替尼(n=101)或安慰剂(n=49),100 mg每日两次共24周,4周无应答者剂量增至150 mg每日两次。
主要发现
- 基线中位血小板计数为16 000/μL;ITP中位病程为8.5年。
- 稳定应答(第14-24周6次双周访视中至少4次血小板≥50 000/μL且未用挽救治疗)福坦替尼组18% vs 安慰剂组2%(P=.0003)。
- 总体应答(回顾性定义为治疗前12周内至少1次血小板≥50 000/μL)福坦替尼组43% vs 安慰剂组14%(P=.0006)。
- 中位应答时间为15天(100 mg每日两次时),83%在8周内应答。
- 最常见不良事件:腹泻(福坦替尼组31% vs 安慰剂组15%)、高血压(28% vs 13%)、恶心(19% vs 8%)、头晕(11% vs 8%)、ALT升高(11% vs 0%)。
关键数值与推荐
- 稳定应答:第14-24周6次双周访视中至少4次血小板≥50 000/μL且未用挽救治疗。
- 总体应答:治疗前12周内至少1次血小板≥50 000/μL(回顾性定义)。
临床怎么用
- 福坦替尼100 mg每日两次起始,4周无应答者增至150 mg每日两次,共24周。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 weeks with a dose increase in nonresponders to 150 mg BID after 4 weeks. The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006). Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 weeks. The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%). Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents). Fostamatinib produced clinically-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab. Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.
引用
- Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018. PMID: 29696684. doi:10.1002/ajh.25125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。